Cancers 2012, 4(4), 1146-1160; doi:10.3390/cancers4041146
Review

Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction

1,* email and 2email
Received: 31 July 2012; in revised form: 23 September 2012 / Accepted: 19 October 2012 / Published: 29 October 2012
(This article belongs to the Special Issue Advances in Cancer Chemoprevention)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Women who are at high risk of breast cancer can be offered chemoprevention. Chemoprevention strategies have expanded over the past decade and include selective receptor modulator inhibitors and aromatase inhibitors. Physicians are expected to provide individualized risk assessments to identify high risk women who may be eligible for chemoprevention. It is prudent that physicians utilize a shared decision approach when counseling high risk women about their preventive options. Barriers and misperceptions however exist with patient and physician acceptance of chemoprevention and continue to impede uptake of chemoprevention as a strategy to reduce breast cancer risk. Programs to increase awareness and elucidate the barriers are critical for women to engage in cancer prevention and promote chemoprevention adherence.
Keywords: aromatase inhibitors; chemoprevention; exemestane; raloxifene; SERMs; tamoxifen
PDF Full-text Download PDF Full-Text [506 KB, uploaded 29 October 2012 10:02 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Layeequr Rahman, R.; Pruthi, S. Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction. Cancers 2012, 4, 1146-1160.

AMA Style

Layeequr Rahman R, Pruthi S. Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction. Cancers. 2012; 4(4):1146-1160.

Chicago/Turabian Style

Layeequr Rahman, Rakhshanda; Pruthi, Sandhya. 2012. "Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction." Cancers 4, no. 4: 1146-1160.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert